Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology
Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.
You may also be interested in...
Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.